首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >Stereoselective interactions of the enantiomers of chromanol 293B with human voltage-gated potassium channels.
【24h】

Stereoselective interactions of the enantiomers of chromanol 293B with human voltage-gated potassium channels.

机译:苯并二氢吡喃酚293B对映异构体与人类电压门控钾通道的立体选择性相互作用。

获取原文
获取原文并翻译 | 示例
           

摘要

Selective inhibitors of the slow component of the cardiac delayed rectifier K(+) current, I(Ks), are of interest as novel class III antiarrhythmic agents and as tools for studying the physiologic roles of the I(Ks) current. Racemic chromanol 293B is an inhibitor of both native I(Ks) and its putative molecular counterpart, the KvLQT1+minK ion channel complex. We synthesized the (+)-[3S,4R] and (-)-[3R,4S] enantiomers of chromanol 293B using chiral intermediates of known absolute configuration and determined their relative potency to block recombinant human K(+) channels that form the basis for the major repolarizing K(+) currents in human heart, including KvLQT1+minK, human ether-a-go-go-related gene product (hERG), Kv1.5, and Kv4.3, corresponding to the slow (I(Ks)), rapid (I(Kr)), and ultrarapid (I(Kur)) delayed rectifier currents and the transient outward current (I(To)), respectively. K(+) channels were expressed in mammalian cells and currents were recorded using the whole-cell patch-clamp technique. We found that the physicochemical properties and relative potency of the enantiomers differed from those reported previously, with (-)-[3R,4S]293B nearly 7-fold more potent in block of KvLQT1+minK than (+)-[3S,4R]293B, indicating that the original stereochemical assignments were reversed. K(+) current inhibition by (-)-293B was selective for KvLQT1+minK over hERG, whereas the stereospecificity of block for KvLQT1+minK and Kv1.5 was preserved, with (-)-293B more potent than (+)-293B for both channel complexes. We conclude that the (-)-[3R,4S] enantiomer of chromanol 293B is a selective inhibitor of KvLQT1+minK and therefore a useful tool for studying I(Ks).
机译:心脏延迟整流器K(+)电流I(Ks)缓慢成分的选择性抑制剂作为新型III类抗心律不齐药物以及研究I(Ks)电流的生理作用的工具而受到关注。外消旋的苯并二氢邻苯二甲酚293B是天然I(Ks)及其推定分子对应物KvLQT1 + minK离子通道复合物的抑制剂。我们使用已知的绝对构型的手性中间体合成了苯并甲醇293B的(+)-[[3S,4R]和(-)-[3R,4S]对映异构体,并确定了它们相对有效的能力来阻断形成人人类心脏中主要的极化K(+)电流的基础,包括KvLQT1 + minK,人类以太相关基因产物(hERG),Kv1.5和Kv4.3,对应于慢速(I (Ks)),快速(I(Kr))和超快速(I(Kur))分别延迟了整流器电流和瞬态向外电流(I(To))。 K(+)通道在哺乳动物细胞中表达,并使用全细胞膜片钳技术记录电流。我们发现对映异构体的理化性质和相对效能与先前报道的不同,其中(-)-[3R,4S] 293B对KvLQT1 + minK的阻滞作用比对(+)-[3S,4R强近7倍] 293B,表明原来的立体化学分配被颠倒了。 (-)-293B对KvLQT1 + minK的K(+)电流抑制作用比hERG有选择性,而KvLQT1 + minK和Kv1.5的阻滞剂的立体特异性得以保留,(-)-293B比(+)-更有效两个通道复合体的293B。我们得出的结论是,苯并三甲酚293B的(-)-[3R,4S]对映异构体是KvLQT1 + minK的选择性抑制剂,因此是研究I(Ks)的有用工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号